CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced its participation in two upcoming events in June:
•13th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Saturday, June 20. At ICML, updated data from the ongoing Phase 1 trial of EZH2 inhibitor tazemetostat (EPZ-6438) in advanced B-cell non-Hodgkin lymphoma (NHL) or advanced solid tumors will be presented at 10:35 a.m. CEST / 4:35 a.m. ET.
Help employers find you! Check out all the jobs and post your resume.
•13th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Saturday, June 20. At ICML, updated data from the ongoing Phase 1 trial of EZH2 inhibitor tazemetostat (EPZ-6438) in advanced B-cell non-Hodgkin lymphoma (NHL) or advanced solid tumors will be presented at 10:35 a.m. CEST / 4:35 a.m. ET.
Help employers find you! Check out all the jobs and post your resume.
